Skip to Content

Tyzeka FDA Approval History

FDA Approved: Yes (Discontinued) (First approved October 25, 2006)
Brand name: Tyzeka
Generic name: telbivudine
Dosage form: Tablets
Company: Novartis Pharmaceuticals Corporation
Treatment for: Hepatitis B

Marketing Status: Discontinued

Tyzeka (telbivudine) is a synthetic thymidine nucleoside analogue indicated for the treatment of chronic hepatitis B.

Development Timeline for Tyzeka

Oct 25, 2006Approval Tyzeka Novartis - Treatment for Chronic Hepatitis B
Jan  3, 2006Idenix and Novartis Announce New Drug Application Submitted to the U.S. Food and Drug Administration for Telbivudine for the Treatment of Chronic Hepatitis B

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.